Mr Jim Read

Biography

Jim Read has more than a decade of experience managing clinical trials data, computer system administration and developing software. Currently they leads a team of six data management professionals within the Global Health Trials Unit at Liverpool School of Tropical Medicine (LSTM). The team supports LSTM trial operations around the world with database development, data management, dashboarding, reports and bespoke software solutions. This allows collaborating teams to maximise the quality of data collection and oversight of endpoints. Jim’s background in full stack software development, big data utilisation, and early adopter innovations equips them to push new concepts and develop systems to maximise efficiency. Since joining LSTM in January 2020, Jim has implemented data warehousing facilities, centralised reporting tools, developed document management software, and implemented a suite of Standard Operating Procedure documents that drive operations. As a member of the Research Integrity Work Group, they support conducting research with best practices and is connected through Research Integrity colleagues to the research culture across the university. Prior to LSTM they worked for the Cancer Trials Unit at the University of Liverpool and has a breadth of experience operating MHRA regulated UK clinical studies and producing systems that support full audits (without major findings).

Research interests

Jim supports the research interests of students, researchers and teachers across LSTM. Their team develops new systems and methodologies for working with and tracking operations using data to provide real time support for data collectors. In combination with the scientific computing team, they are looking to develop in-house artificial intelligence solutions to further enhance data quality and review.

Selected research publications

Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion – Journal: Journal of Antimicrobial Chemotherapy – Published: 4th March 2026

The Effects on the Growth of HIV-exposed Uninfected Infants of Initiating Dolutegravir-based Versus Efavirenz-based cART in Late Pregnancy (DolPHIN-2) – Journal: Pediatric Infectious Disease Journal – Published: 18th July 2025

Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda. – Journal: Value in Health Regional Issues – Published: 1st November 2024

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. – Journal: The Lancet HIV – Published: 1st August 2022

View more publications